Graves' Orbitopathy. Группа авторов

       What Is the Protocol for Cyclosporine?

       What Is the Protocol for Rituximab?

       References

       The Amsterdam Declaration on Graves’ Orbitopathy

      Perros, P. (Newcastle upon Tyne)

       What Is the Amsterdam Declaration?

       Why Was It Proposed?

       Have the Targets Been Met?

       Appendix 1: The Amsterdam Declaration

       Appendix 2: Signatories of the Amsterdam Declaration

       References

       Historical Notes on Graves’ Disease

      Perros, P. (Newcastle upon Tyne)

       Why Bother about History?

       What Is the Earliest Recorded Case of Graves’ Disease and Graves’ Orbitopathy?

       What Were the Early Theories about Graves’ Disease and Graves’ Orbitopathy?

       Who Were the Most Important Contributors in Developing Our Understanding and Treatment of Graves’ Orbitopathy?

       What Lessons Should Be Learnt from the History of Graves’ Disease and Graves’ Orbitopathy?

       References

       Author Index

       Subject Index

Preface to the Third, Revised and Expanded Edition

      It is precisely 10 years ago that the first edition of Graves’ Orbitopathy: A Multidisciplinary Approach was published. The book has become rather popular, warranting a third edition. What has not changed is the successful question-and-answer format of the book. Also, although authors have changed, all are members of EUGOGO adhering to a multidisciplinary approach in the management of Graves’ orbitopathy (GO), preferably in combined thyroid-eye clinics. These EUGOGO principles have been widely adopted, and combined thyroid-eye clinics are now found all over Europe.

      Much has happened in the field of GO in the last 10 years. Patients present now with less severe and less active disease than in the past. Presumably this is related to a secular decline in the prevalence of smoking, and to an earlier diagnosis and treatment of associated Graves’ hyperthyroidism. Novel immunosuppressive treatment modalities have become available. Patient-reported outcomes and the socioeconomic consequences of GO have been given more attention. Actually, we have obtained a better understanding of almost all aspects of GO, and that is duly reflected in the updated text. New chapters have been added on several topics, dealing with comorbidity (diabetes, osteoporosis, dry eye syndrome, glaucoma, cataract, retinopathy), local treatment modalities (artificial tears, prisms, botulinum toxin), novel immunosuppressive treatments (rituximab, teprotumumab, tocilizumab), protocols (selenium, glucocorticoids, retrobulbar irradiation, cyclosporine, rituximab), and questions frequently asked by patients (the patient’s view).

      New centres have become EUGOGO members. EUGOGO remains active in performing clinical and basic research studies, and in organizing annual GO teaching courses with real-life investigation of patients. Formal ETA/EUGOGO guidelines on the management of GO were published in 2016. The third edition of this book reflects very well the continuous activity inside and outside the EUGOGO group on this peculiar thyroid eye disease, which is still one of the remaining enigmas in the field of autoimmune thyroid diseases.

      On behalf of EUGOGO,

      Wilmar M. Wiersinga, Editor

      George J. Kahaly, Co-Editor

       Amsterdam and Mainz, June 2017

Preface to the Second, Revised Edition

      The first edition of Graves’ Orbitopathy: A Multidisciplinary Approach was very well received. We are grateful for the many pieces of positive feedback and constructive comments from our readers. The multidisciplinary approach and the question-and-answer format appear to be a highly successful formula, warranting a second edition of the book within 3 years of the first.

      All chapters have been thoroughly updated, and it is gratifying to see how much progress has been made not only in better understanding the pathogenesis of Graves’ orbitopathy, but also in its treatment. The EUGOGO consensus statement on the management of Graves’ orbitopathy has been accepted worldwide as a useful guideline and is now fully incorporated in the text. Two new chapters have been added: one describing the socioeconomic impact of the disease and the other outlining the Amsterdam Declaration on Graves’ orbitopathy. This declaration, aiming to improve outcomes for thyroid eye disease, was signed by 82 national and international organizations in the field of thyroidology and ophthalmology at the International Symposium on Graves’ Orbitopathy held in October 2009 in Amsterdam on the occasion of the 10th anniversary of EUGOGO.

      We hope the second edition will again contribute to improvements in the quality of care delivered by health professionals to patients with Graves’ orbitopathy.

      On behalf of EUGOGO,

      Wilmar M. Wiersinga, Editor

      George J. Kahaly, Co-Editor

      Amsterdam and Mainz, June 2010

Preface to the First Edition

      We are very pleased to present Graves’ Orbitopathy: A Multidisciplinary Approach.

      The title of the book is a reflection of our opinion that real progress can be made in understanding thyroid eye disease and in improving the outcome of the disfiguring and often invalidating eye changes associated with Graves’ orbitopathy only if specialists of various disciplines work closely together. In other words, we favour a multidisciplinary approach in which internists/endocrinologists, ophthalmologists/orbital surgeons and basic scientists combine their forces. This has been the philosophy since the foundation of EUGOGO, the European Group on Graves’ Orbitopathy, in 1999. The group is currently composed of 13 centres in 8 European countries (Belgium, France, Germany, Greece, Italy,